Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 -- 2944 2022-08-02 08:39:36 |
2 format Meta information modification 2944 2022-08-03 07:16:50 |

Video Upload Options

Do you have a full video?


Are you sure to Delete?
If you have any further questions, please contact Encyclopedia Editorial Office.
Immediata, V.;  Ronchetti, C.;  Spadaro, D.;  Cirillo, F.;  Levi-Setti, P.E. Oxidative Stress and Human Ovarian Response. Encyclopedia. Available online: (accessed on 23 April 2024).
Immediata V,  Ronchetti C,  Spadaro D,  Cirillo F,  Levi-Setti PE. Oxidative Stress and Human Ovarian Response. Encyclopedia. Available at: Accessed April 23, 2024.
Immediata, Valentina, Camilla Ronchetti, Daria Spadaro, Federico Cirillo, Paolo Emanuele Levi-Setti. "Oxidative Stress and Human Ovarian Response" Encyclopedia, (accessed April 23, 2024).
Immediata, V.,  Ronchetti, C.,  Spadaro, D.,  Cirillo, F., & Levi-Setti, P.E. (2022, August 02). Oxidative Stress and Human Ovarian Response. In Encyclopedia.
Immediata, Valentina, et al. "Oxidative Stress and Human Ovarian Response." Encyclopedia. Web. 02 August, 2022.
Oxidative Stress and Human Ovarian Response
Oocyte quality is particularly sensitive to the metabolic endogenous and exogenous environment and a balanced signaling pathway between oxidant and antioxidant forces is fundamental for a proper follicular maturation. Women are born with a finite number of oocytes, and it is of key importance that the health of these oocytes is guaranteed throughout their reproductive life to ensure optimal ovulation, fertilization and subsequent embryonic development. The strategy by which the number and quality of oocytes can be preserved is the augmentation of systems capable of rapidly detecting and repairing DNA damage caused by a normal or abnormal metabolic status or by exposure to exogenous agents. Indeed, DNA damage repair is crucial for the integrity of the cellular genome and to its functionality. Noteworthily, for oocytes, it is essential to correct DNA damage in order to prevent the transmission of any genetic mutation to the offspring.
oxidative stress oocyte quality antioxidants

1. The Importance of Oxidative Balance

ROS are byproducts of cell metabolism, the main ones being superoxide anion (O2•−), hydroxyl radical (OH), peroxyl (ROO), alkoxyl (RO) and hydroperoxyl (H2O2). Their constant production results in lipid peroxidation, protein and nucleic acid damage determining strand breaks, loss and deamination of base, together with loss of DNA repair mechanisms and creation of mutations, all inevitably ending in cell death [1]. However, the impact of ROS on proteins is related to the severity of the oxidative stress and the category of proteins involved [2].
In homeostatic conditions, the presence of antioxidant mechanisms allows a balance between ROS production and reduction. Antioxidants are divided into enzymatic, such as the previously cited catalase, superoxide dismutase (SOD) or glutathione transferase, and non-enzymatic, also defined as dietary supplements, which include vitamin C, vitamin E, β-carotene and zinc.
During oxidative respiration, mitochondria convert a small percentage of oxygen into superoxide, which is then converted to hydroxyl radicals. The latter may damage DNA and cause single-strand breaks (SSBs) that can turn to double-strand breaks (DSBs) when multiple lesions occur close together on antiparallel strands.
Among the different DNA damage types, DSBs are the most detrimental since they imply genomic rearrangements, deletions, translocations and fusions, which cause cellular impairment. The endogenous production of ROS is a major cause of DSBs in somatic [3] but also in germ cells. The spontaneous occurrence of DSBs in oocytes due to the endogenous oxidative stress puts the spotlight on the importance of DNA repair for maintaining oocyte quality [4].
Indeed, in case of oxidant/antioxidant imbalance, unrepaired or incorrectly repaired double-strand breaks (DSBs) may occur [5] and this fact may lead to apoptosis, impaired growth and maturation of the oocyte, infertility [6][7], miscarriages [8][9] or chromosome breaks, translocations, deletions and inversions in the offspring [10][11]. It is well known how chromosomal abnormalities may cause different intellectual and/or physical disabilities, growth retardation and malformations in the offspring, depending on the severity of the chromosomal aberration, or can lead to non-viable embryos.

1.1. Follicular Fluid Redox Involvement in Ovarian Follicle Growth and Ovulation

ROS are not only damaging molecules per se, but, if present in normal concentration, they have a key role in the regulation of many signaling pathways essential for female fertility [12].
The ovarian follicle is an example of a system based on complex signaling pathways necessary for the correct maturation of the oocyte and, as a consequence, for proper fertilization and embryo development [13]. A crucial role in this signaling process is played by the follicular fluid, whose microenvironment components comprising proteins, steroids, metabolites, and also reactive oxygen species (ROS), together orchestrate oocyte maturation and ovulation. In particular, the follicular fluid proteome has become a topic of research in recent years. The majority of the follicular fluid protein derives from the extracellular environment and a significant proportion (around 20%) is made up by enzymes: this evidence suggests that the follicular microenvironment is not only influenced by the surrounding environment in which the follicle develops and maturates, but, due to the presence of enzymes, it also acts as a theatre in which fundamental metabolic pathways take place [14].
Through the analysis of the protein profile of human follicular fluid, the identification of a huge number of acute-phase proteins pointed towards the existence of inflammatory processes at the basis of ovulation. Moreover, the presence of different antioxidant enzymes—such as catalase, superoxide dismutase (SOD) or glutathione transferase—also supports the hypothesis that the follicle is able to protect itself against oxidative stress-induced toxic damages [15].
Studies that analyzed the composition of follicular fluid of women under controlled ovarian stimulation highlighted the presence of enzymatic antioxidants, demonstrating the existence of an antioxidant activity that increases proportionally with the increasing size of follicles [16].
Nevertheless, ROS are not considered only damaging agents in the follicular fluid, but, according to some researchers, “essential” for ovulation: in particular, hydrogen peroxide seems to have a role in the cumulus oophorus enlargement occurring at the pre-ovulatory LH surge [17]. The presence of ROS in the follicular fluid seems to have a role in follicular growth oocyte maturation and ovarian steroidogenesis [18]. Moreover, oxygen deprivation determined by ROS is a trigger for follicular angiogenesis, which is fundamental for ovarian follicle development and maturation. In addition, ROS are responsible for the process of dominant follicle selection by inducing the apoptosis of the other growing follicles [19][20].
Therefore, the follicular fluid, thanks to its antioxidant compounds, is able to prevent the harmful effects of ROS, which, on the other hand, seem to affect the follicular fluid microenvironment not only negatively but also positively by regulating local biological processes.

1.2. Defects in the Mitochondrial Respiratory Chain

Mitochondria are fundamental in generating cellular energy, in the form of ATP, from food intake of glucose, which is converted in pyruvate. Producing ATP, mitochondria release ROS, which, if not counterbalanced, can induce oxidative damage to mitochondrial DNA (mtDNA), mutations or deletions. The higher mutation rate in mtDNA compared with nuclear DNA is due to its proximity to ROS generation and the limited repair capacity due to the lack of repair enzymes [21].
As a consequence of cellular aging, mtDNA exposure to ROS leads to an increase in mutations that compromise the effectiveness of this organelle, limiting cellular energy production. This leads to an impaired ability to support cellular functions, for example, chromosomal segregation in the cell division phases. In mature oocytes, which are nonreplicating cells, aging and the associated decrease in mitochondrial functions can be detrimental for fertility in women.
As the largest cell in multicellular organisms, the oocyte contains a high number of mitochondria, since they must guarantee the energy for its growth, maturation, fertilization and embryo formation [22] via oxidative phosphorylation. After fertilization, sperm mitochondria are rapidly degraded, and so embryonic mitochondria are derived exclusively from the oocyte. As previously mentioned, mtDNA has a scarce antioxidant mechanism and no histone protection, which leads to an often-unsuccessful repair system. Therefore, mtDNA is easily damaged by ROS and the quality of oocyte mitochondria, thus, determines the quality of the embryo. The decline in oocyte quality over the years contributes to a maternal age-related decline in women’s fertility [23].

2. Oocytes Oxidative Stress and Endometriosis

Endometriosis is a common cause of female infertility; however, the pathological mechanisms responsible for endometriosis-related infertility still remain unclear. Moreover, endometriosis-related infertility is characterized by a lower IVF success rate, and a possible explanation can be identified in a lower quality of oocytes [24]. The cause of worse oocyte quality and, consequently, worse fertility outcomes in this category of women may be oxidative stress.
ROS generation influences both the endometrial and peritoneal environment, which not only affects fertilization, implantation and embryo development, but also the triggers formation of peritoneal adhesions, in turn, frequently responsible for tubal infertility [25][26].
In endometriosis, erythrocytes and endometrial cells undergoing apoptosis in the retrograde menstrual blood may determine the recruitment of macrophages, which are responsible for ROS release and lipid peroxidation. The resulting oxidative stress leads to an inflammatory reaction, ending up in an increased concentration of cytokines and other pro-inflammatory molecules [27].
Comparing the peritoneal fluid of patients with endometriosis with that of fertile and unexplained infertile women, statistically lower levels of antioxidant agents, such as peroxide dismutase and glutathione peroxidase, were identified in the first group [28].
On the other hand, it was demonstrated that the presence of antioxidant agents, such as dismutase and catalase, significantly decreases pelvic adhesion formation in endometriosis [29].
Furthermore, in endometriosis-affected women, a statistically significant rise in the levels of lipid peroxide was identified [30].
Further, nitric oxide synthase (NOS) may play a role in the pathogenesis of endometriosis-related infertility. In particular, nitric oxide (NO) and NOS, which are normally present in endometrial endothelial glands, are expressed in higher concentrations in this category of women [31][32][33]. This increased expression of NOS in endometriosis results from an excessive generation of free radicals [34][35].
Moreover, in adenomyosis patients, the presence of NOS in the ectopic endometrium persists throughout the menstrual cycle [36].
Therefore, oxidative stress affects fertility by determining an asynchrony between endometrial receptivity and embryo stage, thus, reducing the implantation rate [37].

3. Oocytes Oxidative Stress and Polycystic Ovary Syndrome

Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders that may be diagnosed during the female reproductive period. This syndrome is characterized by the presence of two or more of the following criteria: chronic oligo-ovulation or anovulation, androgen excess and ovaries with polycystic morphology [38]. Typical manifestations are hyperandrogenism, menstrual dysfunction and infertility, but also metabolic disorders, such as dyslipidemia, insulin resistance and impaired glucose tolerance, which can all lead to higher cardiovascular risk and diabetes mellitus [39]. In PCOS patients, an abnormal ovarian extracellular matrix (ECM) composition has been found [40], which can give rise to the above-listed altered hormone secretion. ECM plays an important role in transmitting signals to cells for their proliferation and differentiation. The stage of follicle growth and regression implies a reorganization of the ovarian ECM. In certain conditions of unbalance between the oxidative/antioxidative forces, there can be a shift towards the oxidative status that may affect the matrix metalloproteinases (MMPs) [41] and their activity of cleavage of various ECM structural proteins [42]. Consequently, in a condition of impaired MMP activity, PCOS may develop [43][44].
Evidence exists on the role of oxidative stress in PCOS [45][46] and many researchers suggested that MMPs may be implicated in the pathogenesis of PCOS through regulating ovarian tissue remodeling [47][48].
Low levels of vitamin D are associated with symptom exacerbation in PCOS; therefore, reduction in vitamin D concentration may be involved in the metabolic and hormonal dysregulation of this clinical condition [49][50].
In addition, a higher prevalence of vitamin D deficiencies among PCOS women was reported in literature [51].
Vitamin D exerts its role on reproduction modulation through acting on vitamin D receptors expressed in GC, influencing the sensitivity to FSH, anti-Mullerian hormone signaling and progesterone synthesis [52][53].
At the level of human ovarian cells, vitamin D not only induces the synthesis of progesterone, but also reduces ROS generation, stimulating the expression of superoxide dismutase (SOD) and catalase [54].
The positive role of exogenous vitamin D administration to infertile PCOS women on follicular differentiation, menstrual regularity and hyperandrogenism reduction was demonstrated by various studies [55][56][57].
Masjedi et al. demonstrated the positive influence of vitamin D in promoting steroidogenesis and antioxidant enzyme activity, and in decreasing ROS production at the level of both normal and PCOS GC. Moreover, their results highlighted, for the first time, the effect of vitamin D supplementation in improving aromatase and 3β-hydroxysteroid dehydrogenase enzyme activities in PCOS GC [58].

4. Oocytes Oxidative Stress and Aging

To date, one of the most challenging topics in female reproductive health is the age-related decline in fertility. Over the years, there is a progressive decrease in ovarian reserve, in terms of oocyte number and quality [59][60]. As known, aneuploidies and the impaired growing of mature oocytes [61] are at the basis of the higher rate of infertility or miscarriages in advanced-age women. By contrast, the earliest stages of oocyte development and the causes of the decrease in oocyte quality with aging are less known and debated, even if oocytes exist as primordial follicles for most of women’s lifetime [4].
DNA damage and loss of DNA repair ability contribute to this age-related decline in fertility. Due to this higher DNA repair capability loss with age, oocytes from older women are more prone to exogenous DNA damaging agents, such as radio- or chemotherapy [62][63]. This may be caused by the fact that older women have a smaller ovarian reserve when starting the radio- or chemotherapy [64]. Furthermore, impairment in DNA DSB repair factors is higher in women affected by premature ovarian aging, suggesting a key role for the DNA repair response in fertility. Indeed, if any defect in repair occurs, it may lead to a reduction in oocyte number in the case of apoptosis or to a loss of oocyte quality in case of cell evasion from death activation.
Moreover, mitochondrial defects play a fundamental role in oocyte aging [65]. Studies have shown that the number of mtDNA copies in human oocytes decreases with advancing maternal age [66] and with the decline in ovarian reserve [67]. While oocytes are dormant during most of the woman’s lifespan, they are exposed to harmful endogenous factors, such as ROS and free radicals, which cause their mtDNA to cluster and mutate. In addition, a DNA fragmentation upregulation of cell-free DNA (cfDNA) levels, as a result of apoptotic or necrotic events [68], is found in follicular fluid samples from patients with ovarian reserve disorders. At last, during oocyte formation, a large amount of ATP is required and provided by mitochondria. As mitochondrial dysfunction is associated with oocyte aging [69], this process can be expected to become impaired with age.

5. Oocytes Oxidative Stress and Cancer Treatment

Although cancer incidence rates in women in their reproductive age has increased in recent years, mortality is hopefully decreasing due to modern medical improvements [70]. On the other hand, survivors must now cope with the long-term consequences of exposure to cancer therapies.
Both radiotherapy and chemotherapy can cause acute ovarian failure (AOF) that may be transient or permanent. Moreover, they can also cause premature ovarian failure (POF) or premature menopause, during which there is a short return of regular menses with a subsequent loss of ovarian function before the age of 40 years.
Concerning radiotherapy, it can cause ovarian damage, leading to early menopause [71]. GCs are the initial target for radiation damage. When the dividing GCs that support the development of follicles are injured, oocyte maturation may be impaired. This lack of ovulation indicates a loss of female fertility. Just after a few hours of irradiation, cell death can be seen in GCs. With prolonged loss of GCs, the oocyte decreases and loses its viability [72].
The effective sterilizing dose (ESD) of fractionated radiotherapy can cause POF immediately after treatment in 97.5% of patients. ESD decreases with increasing patient age due to the natural decline in oocyte number with age [73]. Doses below the ESD can cause DNA damage that do not result in infertility, but on the contrary, can potentially cause genetic disorders in the offspring, although studies provide little evidence of adverse pregnancy outcomes after exposure [74]. This indicates that DNA repair may occur in oocytes after radiotherapy in order to prevent the inheritance of genetic impairments or that damaged oocytes efficiently degenerate via apoptosis [4].
A disappearance of primordial follicles occurs, occasionally with remnants of degenerating follicles. Collagen takes the place of the ovarian cortical stromal cells and the ovary shrinks. Moreover, radiation injury accelerates the process of small-vessel spontaneous sclerosis and myointimal proliferation to the point of occlusion of the vessel lumen, which is typical in aging [75]. In some women, on the other hand, fertility can be preserved if follicles are relatively radioresistant. This can happen in the late stages of maturation when the GCs are less proliferating. Luckily, in modern times, improved antineoplastic agents and planned radiation therapy may limit the ovarian damage.
Among the chemotherapies, the most toxic to ovaries are the alkylating agents (cyclophosphamide, busulphan and dacarbazine) [75][76][77][78], platinum complexes (cisplatin, carboplatin), taxanes (paclitaxel) and the anthracyclin antibiotic doxorubicin (DXR) [79][80] that can cause DNA breaks, ultimately triggering apoptosis [81], originating firstly in the proliferating GCs of growing follicles [82].
GnRH analogues/agonists (GnRH-a) are considered a measure of protection against ovarian damage during chemotherapy by down-regulating the pituitary gonadal axis and inducing ovarian senescence [83], despite randomized controlled trials still providing conflicting results [81].
It is thought that, thanks to the pituitary gonadotropins that induce a dormant status in the ovary, this may prevent the reaching of the growing phase in which follicles are more sensitive to chemotherapy [84].

6. Oocytes Oxidative Stress and Environmental Agents

There are many environmental compounds that act like endocrine disruptors (ED) and interfere with the normal functioning of the endocrine and reproductive systems (e.g., some pesticides, phthalates and phytoestrogens). Importantly, some of these EDs, in particular Bisphenol A (BPA), have been shown to induce DNA damage in both somatic cells [85] and spermatozoa [86]. On the other hand, the direct oocyte impairment caused by DNA damage due to these agents is still not well known.
BPA is an industrial chemical used in the synthesis of polycarbonate plastics and resins contained in food and beverage containers. Since it mimics estrogens and estrogen receptors are expressed in mature oocytes [87], it has been found to increase DNA DSBs and the expression of repair genes [88]. At last, it has been shown to decrease oocyte survival, even in fetal oocytes [89].
Another detrimental environmental toxicant is Benzo(a)pyrene (BaP), a polycyclic aromatic hydrocarbon. BaP is found in cigarette smoke, oils, coal tar, automobile exhaust fumes, margarine, butter, but even in certain foods, such as as fruits, vegetables and cereals. BaP exposure may result in a significant increase in chromosome abnormalities and DNA breaks in oocytes [90].
Ionizing radiation (IR) that may result from the decay of radioactive metals within the Earth [91] in the form of γ-rays and X-rays, is another environmental agent that causes DNA damage within the ovaries [4].


  1. Duan, J.; Kasper, D.L. Oxidative depolymerization of polysaccharides by reactive oxygen/nitrogen species. Glycobiology 2010, 21, 401–409.
  2. Naskalski, J.W.; Bartosz, G. Oxidative modifications of protein structures. Adv. Clin. Chem. 2000, 35, 161–253.
  3. Woodbine, L.; Brunton, H.; Goodarzi, A.A.; Shibata, A.; Jeggo, P.A. Endogenously induced DNA double strand breaks arise in heterochromatic DNA regions and require ataxia telangiectasia mutated and Artemis for their repair. Nucleic Acids Res. 2011, 39, 6986–6997.
  4. Winship, A.L.; Stringer, J.M.; Liew, S.H.; Hutt, K.J. The importance of DNA repair for maintaining oocyte quality in response to anti-cancer treatments, environmental toxins and maternal ageing. Hum. Reprod. Update 2018, 24, 119–134.
  5. Polo, S.E.; Jackson, S.P. Dynamics of DNA damage response proteins at DNA breaks: A focus on protein modifications. Genes Dev. 2011, 25, 409–433.
  6. Kerr, J.B.; Hutt, K.J.; Michalak, E.M.; Cook, M.; Vandenberg, C.J.; Liew, S.H.; Bouillet, P.; Mills, A.; Scott, C.L.; Findlay, J.K.; et al. DNA damage-induced primordial follicle oocyte apoptosis and loss of fertility require TAp63-mediated induction of Puma and Noxa. Mol. Cell 2012, 48, 343–352.
  7. Shaffer, L.G.; Lupski, J.R. Molecular Mechanisms for Constitutional Chromosomal Rearrangements in Humans. Annu. Rev. Genet. 2000, 34, 297–329.
  8. McFadden, D.E.; Friedman, J.M. Chromosome abnormalities in human beings. Mutat. Res. 1997, 396, 129–140.
  9. Zhang, Y.-X.; Zhang, Y.-P.; Gu, Y.; Guan, F.-J.; Li, S.-L.; Xie, J.-S.; Shen, Y.; Wu, B.-L.; Ju, W.; Jenkins, E.; et al. Genetic analysis of first-trimester miscarriages with a combination of cytogenetic karyotyping, microsatellite genotyping and arrayCGH. Clin. Genet. 2009, 75, 133–140.
  10. Ravel, C.; Letur, H.; Le Lannou, D.; Barthelemy, C.; Bresson, J.L.; Siffroi, J.P. High incidence of chromosomal abnormalities in oocyte donors. Fertil. Steril. 2007, 87, 439–441.
  11. Lim, A.S.; Tsakok, M.F. Age-related decline in fertility: A link to degenerative oocytes? Fertil. Steril. 1997, 68, 265–271.
  12. Agarwal, A.; Gupta, S.; Sekhon, L.; Shah, R. Redox Considerations in Female Reproductive Function and Assisted Reproduction: From Molecular Mechanisms to Health Implications. Antioxid. Redox Signal. 2008, 10, 1375–1403.
  13. Gougeon, A. Human ovarian follicular development: From activation of resting follicles to preovulatory maturation. Ann. d’Endocrinol. 2010, 71, 132–143.
  14. Ambekar, A.S.; Nirujogi, R.S.; Srikanth, S.M.; Chavan, S.; Kelkar, D.S.; Hinduja, I.; Zaveri, K.; Prasad, T.K.; Harsha, H.; Pandey, A.; et al. Proteomic analysis of human follicular fluid: A new perspective towards understanding folliculogenesis. J. Proteom. 2013, 87, 68–77.
  15. Angelucci, S.; Ciavardelli, D.; Di Giuseppe, F.; Eleuterio, E.; Sulpizio, M.; Tiboni, G.M.; Giampietro, F.; Palumbo, P.; Di Ilio, C. Proteome analysis of human follicular fluid. Biochim. Biophys. Acta (BBA)-Proteins Proteom. 2006, 1764, 1775–1785.
  16. Kishi, I.; Ohishi, M.; Akiba, Y.; Asada, H.; Konishi, Y.; Nakano, M.; Kamei, K.; Yoshimura, Y.; Maruyama, T. Thioredoxin, an antioxidant redox protein, in ovarian follicles of women undergoing in vitro fertilization. Endocr. J. 2016, 63, 9–20.
  17. Shkolnik, K.; Tadmor, A.; Ben-Dor, S.; Nevo, N.; Galiani, D.; Dekel, N. Reactive oxygen species are indispensable in ovulation. Proc. Natl. Acad. Sci. USA 2011, 108, 1462–1467.
  18. Juengel, J.L.; McNatty, K.P. The role of proteins of the transforming growth factor-beta superfamily in the intraovarian regulation of follicular development. Hum. Reprod. Update 2005, 11, 143–160.
  19. Gordon, J.D.; Mesiano, S.; Zaloudek, C.J.; Jaffe, R.B. Vascular endothelial growth factor localization in human ovary and fallopian tubes: Possible role in reproductive function and ovarian cyst formation. J. Clin. Endocrinol. Metab. 1996, 81, 353–359.
  20. Behrman, H.R.; Kodaman, P.H.; Preston, S.L.; Gao, S. Oxidative stress and the ovary. J. Soc. Gynecol. Investig. 2001, 8 (Suppl. 1), S40–S42.
  21. Chappel, S. The Role of Mitochondria from Mature Oocyte to Viable Blastocyst. Obstet. Gynecol. Int. 2013, 2013, 183024.
  22. May-Panloup, P.; Chretien, M.; Malthiery, Y.; Reynier, P. Mitochondrial DNA in the Oocyte and the Developing Embryo. Curr. Top. Dev. Biol. 2007, 77, 51–83.
  23. Zhang, D.; Keilty, D.; Zhang, Z.; Chian, R. Mitochondria in oocyte aging: Current understanding. Facts Views Vis. ObGyn 2017, 9, 29–38.
  24. Mahutte, N.G.; Arici, A. Endometriosis and assisted reproductive technologies: Are outcomes affected? Curr. Opin. Obstet. Gynecol. 2001, 13, 275–279.
  25. Van Langendonckt, A.; Casanas-Roux, F.; Donnez, J. Oxidative stress and peritoneal endometriosis. Fertil. Steril. 2002, 77, 861–870.
  26. Bedaiwy, M.; Falcone, T. Peritoneal fluid environment in endometriosis. Clinicopathological implications. Minerva Ginecol. 2003, 55, 333–345.
  27. Gupta, S.; Agarwal, A.; Krajcir, N.; Alvarez, J.G. Role of oxidative stress in endometriosis. Reprod. Biomed. Online 2006, 13, 126–134.
  28. Szczepańska, M.; Koźlik, J.; Skrzypczak, J.; Mikołajczyk, M. Oxidative stress may be a piece in the endometriosis puzzle. Fertil. Steril. 2003, 79, 1288–1293.
  29. Portz, D.M.; Elkins, T.E.; White, R.; Warren, J.; Adadevoh, S.; Randolph, J. Oxygen free radicals and pelvic adhesion formation: I. Blocking oxygen free radical toxicity to prevent adhesion formation in an endometriosis model. Int. J. Fertil. 1991, 36, 39–42.
  30. Polak, G.; Kozioł-Montewka, M.; Gogacz, M.; Błaszkowska, I.; Kotarski, J. Total antioxidant status of peritoneal fluid in infertile women. Eur. J. Obstet. Gynecol. Reprod. Biol. 2001, 94, 261–263.
  31. Murphy, A.A.; Palinski, W.; Rankin, S.; Morales, A.J.; Parthasarathy, S. Evidence for Oxidatively Modified Lipid-Protein Complexes in Endometrium and Endometriosis. Fertil. Steril. 1998, 69, 1092–1094.
  32. Khorram, O.; Lessey, B.A. Alterations in expression of endometrial endothelial nitric oxide synthase and alpha(v)beta(3) integrin in women with endometriosis. Fertil. Steril. 2002, 78, 860–864.
  33. Wu, M.-Y. Nitric oxide synthesis is increased in the endometrial tissue of women with endometriosis. Hum. Reprod. 2003, 18, 2668–2671.
  34. Ota, H.; Igarashi, S.; Hatazawa, J.; Tanaka, T. Endothelial nitric oxide synthase in the endometrium during the menstrual cycle in patients with endometriosis and adenomyosis. Fertil. Steril. 1998, 69, 303–308.
  35. Ota, H.; Igarashi, S.; Hatazawa, J.; Tanaka, T. Endometriosis and Free Radicals. Gynecol. Obstet. Investig. 1999, 48, 29–35.
  36. Kamada, Y.; Nakatsuka, M.; Asagiri, K.; Noguchi, S.; Habara, T.; Takata, M.; Kudo, T. GnRH agonist-suppressed expression of nitric oxide synthases and generation of peroxynitrite in adenomyosis. Hum. Reprod. 2000, 15, 2512–2519.
  37. Nuojua-Huttunen, S.; Tomas, C.; Bloigu, R.; Tuomivaara, L.; Martikainen, H. Intrauterine insemination treatment in subfertility: An analysis of factors affecting outcome. Hum. Reprod. 1999, 14, 698–703.
  38. ESHRE, T.R.; ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril. 2004, 81, 19–25.
  39. Talbott, E.O.; Guzick, D.S.; Sutton-Tyrrell, K.; McHugh-Pemu, K.P.; Zborowski, J.V.; Remsberg, K.E.; Kuller, L.H. Evidence for Association between Polycystic Ovary Syndrome and Premature Carotid Atherosclerosis in Middle-Aged Women. Arter. Thromb. Vasc. Biol. 2000, 20, 2414–2421.
  40. Fedorcsák, P.; Poleć, A.; Ráki, M.; Holm, R.; Jebsen, P.; Åbyholm, T. Differential Release of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases by Human Granulosa-Lutein Cells and Ovarian Leukocytes. Endocrinology 2010, 151, 1290–1298.
  41. Surazynski, A.; Liu, Y.; Miltyk, W.; Phang, J.M. Nitric oxide regulates prolidase activity by serine/threonine phosphorylation. J. Cell. Biochem. 2005, 96, 1086–1094.
  42. Visse, R.; Nagase, H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ. Res. 2003, 92, 827–839.
  43. Lahav-Baratz, S.; Kraiem, Z.; Shiloh, H.; Koifman, M.; Ishai, D.; Dirnfeld, M. Decreased expression of tissue inhibitor of matrix metalloproteinases in follicular fluid from women with polycystic ovaries compared with normally ovulating patients undergoing in vitro fertilization. Fertil. Steril. 2003, 79, 567–571.
  44. Baka, S.; Zourla, K.; Kouskouni, E.; Makrakis, E.; Demeridou, S.; Tzanakaki, D.; Hassiakos, D.; Creatsas, G. Matrix metalloproteinases 2 and 9 and their tissue inhibitors in the follicular fluid of patients with polycystic ovaries undergoing in vitro fertilisation. In Vivo 2010, 24, 293–296.
  45. Murri, M.; Luque-Ramírez, M.; Insenser, M.; Ojeda, M.; Escobar-Morreale, H.F. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): A systematic review and meta-analysis. Hum. Reprod. Update 2013, 19, 268–288.
  46. Zuo, T.; Zhu, M.; Xu, W. Roles of Oxidative Stress in Polycystic Ovary Syndrome and Cancers. Oxidative Med. Cell. Longev. 2016, 2016, 8589318.
  47. Hilali, N.; Vural, M.; Camuzcuoglu, H.; Camuzcuoglu, A.; Aksoy, N. Increased prolidase activity and oxidative stress in PCOS. Clin. Endocrinol. 2013, 79, 105–110.
  48. Liu, B.; Cai, L.-Y.; Lv, H.-M.; Xia, L.; Zhang, Y.-J.; Zhang, H.-X.; Guan, Y.-M. Raised serum levels of matrix metalloproteinase-9 in women with polycystic ovary syndrome and its association with insulin-like growth factor binding protein-1. Gynecol. Endocrinol. 2008, 24, 285–288.
  49. He, C.; Lin, Z.; Robb, S.W.; Ezeamama, A.E. Serum Vitamin D Levels and Polycystic Ovary syndrome: A Systematic Review and Meta-Analysis. Nutrients 2015, 7, 4555–4577.
  50. Krul-Poel, Y.H.M.; Snackey, C.; Louwers, Y.; Lips, P.; Lambalk, C.B.; Laven, J.S.E.; Simsek, S. The role of vitamin D in metabolic disturbances in polycystic ovary syndrome: A systematic review. Eur. J. Endocrinol. 2013, 169, 853–865.
  51. Thomson, R.L.; Spedding, S.; Buckley, J. Vitamin D in the aetiology and management of polycystic ovary syndrome. Clin. Endocrinol. 2012, 77, 343–350.
  52. Merhi, Z.; Doswell, A.; Krebs, K.; Cipolla, M. Vitamin D Alters Genes Involved in Follicular Development and Steroidogenesis in Human Cumulus Granulosa Cells. J. Clin. Endocrinol. Metab. 2014, 99, E1137–E1145.
  53. Parikh, G.; Varadinova, M.; Suwandhi, P.; Araki, T.; Rosenwaks, Z.; Poretsky, L.; Seto-Young, D. Vitamin D Regulates Steroidogenesis and Insulin-like Growth Factor Binding Protein-1 (IGFBP-1) Production in Human Ovarian Cells. Horm. Metab. Res. 2010, 42, 754–757.
  54. Yao, X.; Zhang, G.; Guo, Y.; Ei-Samahy, M.; Wang, S.; Wan, Y.; Han, L.; Liu, Z.; Wang, F.; Zhang, Y. Vitamin D receptor expression and potential role of vitamin D on cell proliferation and steroidogenesis in goat ovarian granulosa cells. Theriogenology 2017, 102, 162–173.
  55. Fang, F.; Ni, K.; Cai, Y.; Shang, J.; Zhang, X.; Xiong, C. Effect of vitamin D supplementation on polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials. Complementary Ther. Clin. Pract. 2017, 26, 53–60.
  56. Firouzabadi, R.D.; Aflatoonian, A.; Modarresi, S.; Sekhavat, L.; MohammadTaheri, S. Therapeutic effects of calcium & vitamin D supplementation in women with PCOS. Complementary Ther. Clin. Pract. 2012, 18, 85–88.
  57. Pal, L.; Berry, A.; Coraluzzi, L.; Kustan, E.; Danton, C.; Shaw, J.; Taylor, H. Therapeutic implications of vitamin D and calcium in overweight women with polycystic ovary syndrome. Gynecol. Endocrinol. 2012, 28, 965–968.
  58. Masjedi, F.; Keshtgar, S.; Zal, F.; Talaei-Khozani, T.; Sameti, S.; Fallahi, S.; Kazeroni, M. Effects of vitamin D on steroidogenesis, reactive oxygen species production, and enzymatic antioxidant defense in human granulosa cells of normal and polycystic ovaries. J. Steroid Biochem. Mol. Biol. 2020, 197, 105521.
  59. Tatone, C. Oocyte senescence: A firm link to age-related female subfertility. Gynecol. Endocrinol. 2008, 24, 59–63.
  60. Balasch, J.; Gratacós, E. Delayed childbearing: Effects on fertility and the outcome of pregnancy. Curr. Opin. Obstet. Gynecol. 2012, 24, 187–193.
  61. Hassold, T.; Hall, H.; Hunt, P. The origin of human aneuploidy: Where we have been, where we are going. Hum. Mol. Genet. 2007, 16, R203–R208.
  62. Petrek, J.A.; Naughton, M.J.; Case, L.D.; Paskett, E.D.; Naftalis, E.Z.; Singletary, S.E.; Sukumvanich, P. Incidence, Time Course, and Determinants of Menstrual Bleeding After Breast Cancer Treatment: A Prospective Study. J. Clin. Oncol. 2006, 24, 1045–1051.
  63. Letourneau, J.M.; Ebbel, E.E.; Katz, P.P.; Katz, A.; Ai, W.Z.; Chien, A.J.; Melisko, M.E.; Cedars, M.I.; Rosen, M.P. Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer 2012, 118, 1710–1717.
  64. Meirow, D.; Biederman, H.; Anderson, R.A.; Wallace, W.H.B. Toxicity of Chemotherapy and Radiation on Female Reproduction. Clin. Obstet. Gynecol. 2010, 53, 727–739.
  65. Barritt, J.A.; Cohen, J.; Brenner, C.A. Mitochondrial DNA point mutation in human oocytes is associated with maternal age. Reprod. Biomed. Online 2000, 1, 96–100.
  66. Konstantinidis, M.; Alfarawati, S.; Hurd, D.; Paolucci, M.; Shovelton, J.; Fragouli, E.; Wells, D. Simultaneous assessment of aneuploidy, polymorphisms, and mitochondrial DNA content in human polar bodies and embryos with the use of a novel microarray platform. Fertil. Steril. 2014, 102, 1385–1392.
  67. Suganuma, N.; Kitagawa, T.; Nawa, A.; Tomoda, Y. Human Ovarian Aging and Mitochondrial DNA Deletion. Horm. Res. 1993, 39 (Suppl. 1), 16–21.
  68. Traver, S.; Scalici, E.; Mullet, T.; Molinari, N.; Vincens, C.; Anahory, T.; Hamamah, S. Cell-free DNA in Human Follicular Microenvironment: New Prognostic Biomarker to Predict in vitro Fertilization Outcomes. PLoS ONE 2015, 10, e0136172.
  69. Bentov, Y.; Yavorska, T.; Esfandiari, N.; Jurisicova, A.; Casper, R.F. The contribution of mitochondrial function to reproductive aging. J. Assist. Reprod. Genet. 2011, 28, 773–783.
  70. Smith, A.W.; Keegan, T.; Hamilton, A.; Lynch, C.; Wu, X.-C.; Schwartz, S.M.; Kato, I.; Cress, R.; Harlan, L.; AYA HOPE Study Collaborative Group. Understanding care and outcomes in adolescents and young adults with cancer: A review of the AYA HOPE study. Pediatr. Blood Cancer 2019, 66, e27486.
  71. Wallace, W.H.B.; Thomson, A.B.; Kelsey, T. The radiosensitivity of the human oocyte. Hum. Reprod. 2003, 18, 117–121.
  72. Kim, S.; Kim, S.W.; Han, S.J.; Lee, S.; Park, H.T.; Song, J.Y.; Kim, T. Molecular Mechanism and Prevention Strategy of Chemotherapy- and Radiotherapy-Induced Ovarian Damage. Int. J. Mol. Sci. 2021, 22, 7484.
  73. Wallace, W.H.B.; Thomson, A.B.; Saran, F.; Kelsey, T.W. Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int. J. Radiat. Oncol. 2005, 62, 738–744.
  74. Adriaens, I.; Smitz, J.; Jacquet, P. The current knowledge on radiosensitivity of ovarian follicle development stages. Hum. Reprod. Update 2009, 15, 359–377.
  75. Stroud, J.S.; Mutch, D.; Rader, J.; Powell, M.; Thaker, P.H.; Grigsby, P.W. Effects of cancer treatment on ovarian function. Fertil. Steril. 2009, 92, 417–427.
  76. Thomson, A.B.; Critchley, H.O.; Wallace, W.H. Fertility and progeny. Eur. J. Cancer 2002, 38, 1634–1644.
  77. Chemaitilly, W.; Mertens, A.C.; Mitby, P.; Whitton, J.; Stovall, M.; Yasui, Y.; Robison, L.L.; Sklar, C.A. Acute Ovarian Failure in the Childhood Cancer Survivor Study. J. Clin. Endocrinol. Metab. 2006, 91, 1723–1728.
  78. Kalich-Philosoph, L.; Roness, H.; Carmely, A.; Fishel-Bartal, M.; Ligumsky, H.; Paglin, S.; Wolf, I.; Kanety, H.; Sredni, B.; Meirow, D. Cyclophosphamide Triggers Follicle Activation and “Burnout”; AS101 Prevents Follicle Loss and Preserves Fertility. Sci. Transl. Med. 2013, 5, 185ra62.
  79. Ben-Aharon, I.; Bar-Joseph, H.; Tzarfaty, G.; Kuchinsky, L.; Rizel, S.; Stemmer, S.M.; Shalgi, R. Doxorubicin-induced ovarian toxicity. Reprod. Biol. Endocrinol. 2010, 8, 20.
  80. Spears, N.; Lopes, F.; Stefansdottir, A.; Rossi, V.; De Felici, M.; Anderson, R.A.; Klinger, F.G. Ovarian damage from chemotherapy and current approaches to its protection. Hum. Reprod. Update 2019, 25, 673–693.
  81. Roness, H.; Kashi, O.; Meirow, D. Prevention of chemotherapy-induced ovarian damage. Fertil. Steril. 2016, 105, 20–29.
  82. Utsunomiya, T.; Tanaka, T.; Utsunomiya, H.; Umesaki, N. A novel molecular mechanism for anticancer drug-induced ovarian failure: Irinotecan HCl, an anticancer topoisomerase I inhibitor, induces specific FasL expression in granulosa cells of large ovarian follicles to enhance follicular apoptosis. Int. J. Oncol. 2008, 32, 991–1000.
  83. Blumenfeld, Z.; von Wolff, M. GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy. Hum. Reprod. Update 2008, 14, 543–552.
  84. Molina, J.R.; Barton, D.L.; Loprinzi, C.L. Chemotherapy-induced ovarian failure: Manifestations and management. Drug Saf. 2005, 28, 401–416.
  85. Basu, A.K. DNA Damage, Mutagenesis and Cancer. Int. J. Mol. Sci. 2018, 19, 970.
  86. Meeker, J.D.; Ehrlich, S.; Toth, T.L.; Wright, D.L.; Calafat, A.M.; Trisini, A.T.; Ye, X.; Hauser, R. Semen quality and sperm DNA damage in relation to urinary bisphenol A among men from an infertility clinic. Reprod. Toxicol. 2010, 30, 532–539.
  87. Tang, Z.-R.; Zhang, R.; Lian, Z.-X.; Deng, S.-L.; Yu, K. Estrogen-Receptor Expression and Function in Female Reproductive Disease. Cells 2019, 8, 1123.
  88. Brieño-Enríquez, M.; Robles, P.; Camats-Tarruella, N.; García-Cruz, R.; Roig, I.; Cabero, L.; Martínez, F.; Caldés, M.G. Human meiotic progression and recombination are affected by Bisphenol A exposure during in vitro human oocyte development. Hum. Reprod. 2011, 26, 2807–2818.
  89. Brieño-Enriquez, M.A.; Reig-Viader, R.; Cabero, L.; Toran, N.; Martinez, F.; Roig, I.; Caldes, M.G. Gene expression is altered after bisphenol A exposure in human fetal oocytes in vitro. Mol. Hum. Reprod. 2012, 18, 171–183.
  90. Shamsuddin, A.; Gan, R. Immunocytochemical localization of benzo(a)pyrene-DNA adducts in human tissues. Hum. Pathol. 1988, 19, 309–315.
  91. Lieber, M.R. The Mechanism of Double-Strand DNA Break Repair by the Nonhomologous DNA End-Joining Pathway. Annu. Rev. Biochem. 2010, 79, 181–211.
Subjects: Others
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to : , , , ,
View Times: 276
Revisions: 2 times (View History)
Update Date: 03 Aug 2022